Vitamin c in Diabetes

Effects of ascorbic acid on AGEs, AOPP ,FRAP, hsp70,hsCRP, ox- LDL ,leptinand HOMA in patients with type 2diabetes

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160811029306N1

Enrollment

Registered

2018-10-06

Start date

2018-10-23

Completion date

Unknown

Last updated

2018-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Diabetes mellitus due to underlying condition

Interventions

Intervention 1: Intervention group: Oral Vitamin c supplement. Intervention 2: Control group: placebo.

Eligibility

Sex/Gender

All

Age

30 Years to 65 Years

Inclusion criteria

Inclusion criteria: type2 diabetes older than 30

Exclusion criteria

Exclusion criteria: type1 diabetes pregnancy renal failure history ofheart failure liver failure malignancy smoking acute inflammation infection hypersensitivity to vitamin C current vitamins use

Design outcomes

Primary

Measure	Time frame
Advancedglycation end products(AGEs). Timepoint: Blood samples will be taken before treatment and after 2 month of treatment. Method of measurement: AGEs will be measured by the spectrophotometric method in endocrine laboratory of vali-asr hospital.;AOPP. Timepoint: Blood samples will be taken before treatment and after 2 month of treatment. Method of measurement: AOPP concentrations will be measured by spectrophotometric methods.;FRAP. Timepoint: Blood samples will be taken before treatment and after 2 month of treatment. Method of measurement: FRAP will be assessed by spectrophotometric method.;Ox LDL. Timepoint: Blood samples will be taken before treatment and after 2 month of treatment. Method of measurement: OX LDL will be measured using commercially available sandwich enzymelinked immunosorbent assay.;HSP70. Timepoint: Blood samples will be taken before treatment and after 2 month of treatment. Method of measurement: HSP70 will be measured using a quantitative sandwich ELISA immunoassay.;Hs-CRP. Timepoint: Blood samples will be taken before treatment and after 2 month of treatment. Method of measurement: Hs-CRP will be assessed by a two-site enzyme-linked immunosorbent assay.;Leptin. Timepoint: Blood samples will be taken before treatment and after 2 month of treatment. Method of measurement: Leptin leptin concentration will be measured by an ELISA assay.;Insulin. Timepoint: Blood samples will be taken before treatment and after 2 month of treatment. Method of measurement: Fasting insulin was measured using radioimmunoassay techniques.	—

Measure

Time frame

Advancedglycation end products(AGEs). Timepoint: Blood samples will be taken before treatment and after 2 month of treatment. Method of measurement: AGEs will be measured by the spectrophotometric method in endocrine laboratory of vali-asr hospital.;AOPP. Timepoint: Blood samples will be taken before treatment and after 2 month of treatment. Method of measurement: AOPP concentrations will be measured by spectrophotometric methods.;FRAP. Timepoint: Blood samples will be taken before treatment and after 2 month of treatment. Method of measurement: FRAP will be assessed by spectrophotometric method.;Ox LDL. Timepoint: Blood samples will be taken before treatment and after 2 month of treatment. Method of measurement: OX LDL will be measured using commercially available sandwich enzymelinked immunosorbent assay.;HSP70. Timepoint: Blood samples will be taken before treatment and after 2 month of treatment. Method of measurement: HSP70 will be measured using a quantitative sandwich ELISA immunoassay.;Hs-CRP. Timepoint: Blood samples will be taken before treatment and after 2 month of treatment. Method of measurement: Hs-CRP will be assessed by a two-site enzyme-linked immunosorbent assay.;Leptin. Timepoint: Blood samples will be taken before treatment and after 2 month of treatment. Method of measurement: Leptin leptin concentration will be measured by an ELISA assay.;Insulin. Timepoint: Blood samples will be taken before treatment and after 2 month of treatment. Method of measurement: Fasting insulin was measured using radioimmunoassay techniques.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactManouchehr Nakhjavani

Tehran University of Medical Sciences

nakhjavanim@tums.ac.ir+98 21 6691 1294

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 8, 2026